Publications – Pioneering The Molecular Diagnostic Field2025-05-08T17:02:40-07:00

Publications

Publications

FEATURED PUBLICATIONS

Comparison of Complete Genomics DNBSEQ-G99 Sequencer and Illumina® MiSeqTM using Invivoscribe’s FLT3 ITD MRD Assay and NPM1 MRD Assay

November 8th, 2024|

VIEW PUBLICATION ⟶

Performance Comparison of Invivoscribe’s LymphoTrack® Assays Between Complete Genomics DNBSEQ-G99 and Illumina® MiSeqTM NGS Platforms

November 8th, 2024|

VIEW PUBLICATION ⟶

LATEST PUBLICATIONS

Comparison of Complete Genomics DNBSEQ-G99 Sequencer and Illumina® MiSeqTM using Invivoscribe’s FLT3 ITD MRD Assay and NPM1 MRD Assay

VIEW PUBLICATION ⟶

November 8th, 2024|

Performance Comparison of Invivoscribe’s LymphoTrack® Assays Between Complete Genomics DNBSEQ-G99 and Illumina® MiSeqTM NGS Platforms

VIEW PUBLICATION ⟶

November 8th, 2024|

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

VIEW PUBLICATION ⟶

March 20th, 2024|

Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal residual disease detection in Chinese patients with multiple myeloma

VIEW PUBLICATION ⟶

March 19th, 2024|

Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms

VIEW PUBLICATION ⟶

March 1st, 2024|

Leveraging Standardized MRD Assays to Guide CLL Treatment

VIEW PUBLICATION ⟶

January 25th, 2024|

Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

VIEW PUBLICATION ⟶

March 23rd, 2023|

Minimal/Measurable Residual Disease (MRD) Monitoring in Patients with Lymphoid Neoplasms by High-Throughput Sequencing of the T-Cell Receptor

VIEW PUBLICATION ⟶

March 2nd, 2023|

Comparing Data Generated Using Multiparametric Flow Cytometry, Capillary Electrophoresis, and Next-Generation Sequencing in a Cohort of B-Cell Lymphoproliferative Disorder Samples

VIEW PUBLICATION ⟶

November 15th, 2022|

LymphoTrack Is Equally Sensitive as PCR GeneScan and Sanger Sequencing for Detection of Clonal Rearrangements in ALL Patients

VIEW PUBLICATION ⟶

June 4th, 2022|

Immunoglobulin Heavy Chain High-Throughput Sequencing in Pediatric B-Precursor Acute Lymphoblastic Leukemia: Is the Clonality of the Disease at Diagnosis Related to Its Prognosis?

VIEW PUBLICATION ⟶

May 30th, 2022|

Real-world data on prognostic value of measurable residual disease assessment by fragment analysis or next-generation sequencing in multiple myeloma

VIEW PUBLICATION ⟶

May 3rd, 2022|

Ig Gene Clonality Analysis Using Next-Generation Sequencing for Improved Minimal Residual Disease Detection with Significant Prognostic Value in Multiple Myeloma Patients

VIEW PUBLICATION ⟶

January 4th, 2022|

NGS Analysis of Clonality and Minimal Residual Disease in a Patient with Concurrent Richter’s Transformation and CLL/SLL

VIEW PUBLICATION ⟶

December 28th, 2021|

Plan for a Successful International Drug Approval with Early Development of the Accompanying CDx

VIEW PUBLICATION ⟶

December 8th, 2021|

Machine Learning Algorithms Accelerate Throughput of a Flow – Sequencing Cell Based Assay for an Acute Myeloid Leukemia (AML) Therapeutic Discovery Platform

VIEW PUBLICATION ⟶

November 5th, 2021|

Immunoglobulin gene rearrangement in Koreans with multiple myeloma: Clonality assessment and repertoire analysis using next-generation sequencing

VIEW PUBLICATION ⟶

June 24th, 2021|

Feasibility of cell-free DNA collection and clonal immunoglobulin sequencing in South African patients with HIV-associated lymphoma

VIEW PUBLICATION ⟶

April 28th, 2021|

Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

VIEW PUBLICATION ⟶

April 20th, 2021|

Validation and interpretation of IGH and TCR clonality testing by Ion Torrent S5 NGS for diagnosis and disease monitoring in B and T cell cancers

VIEW PUBLICATION ⟶

November 25th, 2020|

Classification of intestinal T‐cell receptor repertoires using machine learning methods can identify patients with coeliac disease regardless of dietary gluten status

VIEW PUBLICATION ⟶

November 22nd, 2020|

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

VIEW PUBLICATION ⟶

October 30th, 2020|

Evaluation of the polymerase chain reaction–based T-cell receptor β clonality test in the diagnosis of early mycosis fungoides

VIEW PUBLICATION ⟶

June 8th, 2020|

Quantitation of CMV Specific T-Cell Expansion Using T Cell Receptor Beta Locus Deep Sequencing to Identify Patients at Risk of Viral Complications

VIEW PUBLICATION ⟶

March 1st, 2020|

Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

VIEW PUBLICATION ⟶

February 6th, 2020|

Plasma Cell Myeloma Residual Disease Quantitation Using a Next-Generation Sequencing-Based IGH Clonal Rearrangement Assay with the Aid of a “Spike-in” Clonal Sequence

VIEW PUBLICATION ⟶

November 13th, 2019|

Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implications

VIEW PUBLICATION ⟶

October 15th, 2019|

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

VIEW PUBLICATION ⟶

March 21st, 2019|

Clinical-scale Rapid Autologous BK-virus Specific T Cell Line generation from Kidney Transplant Recipients with Active Viremia for Adoptive Immunotherapy

VIEW PUBLICATION ⟶

November 11th, 2017|

Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)

VIEW PUBLICATION ⟶

August 9th, 2017|

Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia

VIEW PUBLICATION ⟶

July 3rd, 2017|

In vitro co-expression of human amyloidogenic immunoglobulin light and heavy chain proteins: a relevant cell-based model of AL amyloidosis

VIEW PUBLICATION ⟶

June 20th, 2017|

A Small Case Series of Intravascular Large B-Cell Lymphoma with Unexpected Findings: Subset of Cases with Concomitant Extravascular Central Nervous System (CNS) Involvement Mimicking Primary CNS Lymphoma

VIEW PUBLICATION ⟶

April 17th, 2017|

Discordant Lymphoma Consisting of Mediastinal Large B-Cell Lymphoma and Nodular Sclerosis Hodgkin Lymphoma in the Right Supraclavicular Lymph Nodes: A Case Report

VIEW PUBLICATION ⟶

December 29th, 2015|

Molecular Genetic Data Favoring a Sequential Clonal Transformation of a Large B Cell Lymphoma into an Anaplastic Large T Cell Lymphoma, ALK-Negative

VIEW PUBLICATION ⟶

December 1st, 2015|

Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia

VIEW PUBLICATION ⟶

March 18th, 2015|

EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations

VIEW PUBLICATION ⟶

October 26th, 2012|

Application of cost–effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia

VIEW PUBLICATION ⟶

March 30th, 2011|

IMGT/JunctionAnalysis: the first tool for the analysis of the immunoglobulin and T cell receptor complex V–J and V–D–J JUNCTIONs

VIEW PUBLICATION ⟶

August 4th, 2004|

Comparison of Complete Genomics DNBSEQ-G99 Sequencer and Illumina® MiSeqTM using Invivoscribe’s FLT3 ITD MRD Assay and NPM1 MRD Assay

VIEW PUBLICATION ⟶

November 8th, 2024|

Performance Comparison of Invivoscribe’s LymphoTrack® Assays Between Complete Genomics DNBSEQ-G99 and Illumina® MiSeqTM NGS Platforms

VIEW PUBLICATION ⟶

November 8th, 2024|

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

VIEW PUBLICATION ⟶

March 20th, 2024|

Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal residual disease detection in Chinese patients with multiple myeloma

VIEW PUBLICATION ⟶

March 19th, 2024|

Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms

VIEW PUBLICATION ⟶

March 1st, 2024|

Leveraging Standardized MRD Assays to Guide CLL Treatment

VIEW PUBLICATION ⟶

January 25th, 2024|

Comparison of Complete Genomics DNBSEQ-G99 Sequencer and Illumina® MiSeqTM using Invivoscribe’s FLT3 ITD MRD Assay and NPM1 MRD Assay

VIEW PUBLICATION ⟶

November 8th, 2024|

Performance Comparison of Invivoscribe’s LymphoTrack® Assays Between Complete Genomics DNBSEQ-G99 and Illumina® MiSeqTM NGS Platforms

VIEW PUBLICATION ⟶

November 8th, 2024|

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

VIEW PUBLICATION ⟶

March 20th, 2024|

Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal residual disease detection in Chinese patients with multiple myeloma

VIEW PUBLICATION ⟶

March 19th, 2024|

Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms

VIEW PUBLICATION ⟶

March 1st, 2024|

Leveraging Standardized MRD Assays to Guide CLL Treatment

VIEW PUBLICATION ⟶

January 25th, 2024|

Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

VIEW PUBLICATION ⟶

March 23rd, 2023|

Minimal/Measurable Residual Disease (MRD) Monitoring in Patients with Lymphoid Neoplasms by High-Throughput Sequencing of the T-Cell Receptor

VIEW PUBLICATION ⟶

March 2nd, 2023|

Comparing Data Generated Using Multiparametric Flow Cytometry, Capillary Electrophoresis, and Next-Generation Sequencing in a Cohort of B-Cell Lymphoproliferative Disorder Samples

VIEW PUBLICATION ⟶

November 15th, 2022|

LymphoTrack Is Equally Sensitive as PCR GeneScan and Sanger Sequencing for Detection of Clonal Rearrangements in ALL Patients

VIEW PUBLICATION ⟶

June 4th, 2022|

Immunoglobulin Heavy Chain High-Throughput Sequencing in Pediatric B-Precursor Acute Lymphoblastic Leukemia: Is the Clonality of the Disease at Diagnosis Related to Its Prognosis?

VIEW PUBLICATION ⟶

May 30th, 2022|

Real-world data on prognostic value of measurable residual disease assessment by fragment analysis or next-generation sequencing in multiple myeloma

VIEW PUBLICATION ⟶

May 3rd, 2022|

Ig Gene Clonality Analysis Using Next-Generation Sequencing for Improved Minimal Residual Disease Detection with Significant Prognostic Value in Multiple Myeloma Patients

VIEW PUBLICATION ⟶

January 4th, 2022|

Feasibility of cell-free DNA collection and clonal immunoglobulin sequencing in South African patients with HIV-associated lymphoma

VIEW PUBLICATION ⟶

April 28th, 2021|

NGS Analysis of Clonality and Minimal Residual Disease in a Patient with Concurrent Richter’s Transformation and CLL/SLL

VIEW PUBLICATION ⟶

December 28th, 2021|

Plan for a Successful International Drug Approval with Early Development of the Accompanying CDx

VIEW PUBLICATION ⟶

December 8th, 2021|

Machine Learning Algorithms Accelerate Throughput of a Flow – Sequencing Cell Based Assay for an Acute Myeloid Leukemia (AML) Therapeutic Discovery Platform

VIEW PUBLICATION ⟶

November 5th, 2021|

Immunoglobulin gene rearrangement in Koreans with multiple myeloma: Clonality assessment and repertoire analysis using next-generation sequencing

VIEW PUBLICATION ⟶

June 24th, 2021|

Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

VIEW PUBLICATION ⟶

April 20th, 2021|

Validation and interpretation of IGH and TCR clonality testing by Ion Torrent S5 NGS for diagnosis and disease monitoring in B and T cell cancers

VIEW PUBLICATION ⟶

November 25th, 2020|

Classification of intestinal T‐cell receptor repertoires using machine learning methods can identify patients with coeliac disease regardless of dietary gluten status

VIEW PUBLICATION ⟶

November 22nd, 2020|

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

VIEW PUBLICATION ⟶

October 30th, 2020|

Evaluation of the polymerase chain reaction–based T-cell receptor β clonality test in the diagnosis of early mycosis fungoides

VIEW PUBLICATION ⟶

June 8th, 2020|

Quantitation of CMV Specific T-Cell Expansion Using T Cell Receptor Beta Locus Deep Sequencing to Identify Patients at Risk of Viral Complications

VIEW PUBLICATION ⟶

March 1st, 2020|

Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

VIEW PUBLICATION ⟶

February 6th, 2020|

Plasma Cell Myeloma Residual Disease Quantitation Using a Next-Generation Sequencing-Based IGH Clonal Rearrangement Assay with the Aid of a “Spike-in” Clonal Sequence

VIEW PUBLICATION ⟶

November 13th, 2019|

Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implications

VIEW PUBLICATION ⟶

October 15th, 2019|

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

VIEW PUBLICATION ⟶

March 21st, 2019|

Clinical-scale Rapid Autologous BK-virus Specific T Cell Line generation from Kidney Transplant Recipients with Active Viremia for Adoptive Immunotherapy

VIEW PUBLICATION ⟶

November 11th, 2017|

Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)

VIEW PUBLICATION ⟶

August 9th, 2017|

Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia

VIEW PUBLICATION ⟶

July 3rd, 2017|

In vitro co-expression of human amyloidogenic immunoglobulin light and heavy chain proteins: a relevant cell-based model of AL amyloidosis

VIEW PUBLICATION ⟶

June 20th, 2017|

A Small Case Series of Intravascular Large B-Cell Lymphoma with Unexpected Findings: Subset of Cases with Concomitant Extravascular Central Nervous System (CNS) Involvement Mimicking Primary CNS Lymphoma

VIEW PUBLICATION ⟶

April 17th, 2017|
Archived Publications

Discordant Lymphoma Consisting of Mediastinal Large B-Cell Lymphoma and Nodular Sclerosis Hodgkin Lymphoma in the Right Supraclavicular Lymph Nodes: A Case Report

VIEW PUBLICATION ⟶

December 29th, 2015|

Molecular Genetic Data Favoring a Sequential Clonal Transformation of a Large B Cell Lymphoma into an Anaplastic Large T Cell Lymphoma, ALK-Negative

VIEW PUBLICATION ⟶

December 1st, 2015|

Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia

VIEW PUBLICATION ⟶

March 18th, 2015|

EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations

VIEW PUBLICATION ⟶

October 26th, 2012|

Application of cost–effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia

VIEW PUBLICATION ⟶

March 30th, 2011|

IMGT/JunctionAnalysis: the first tool for the analysis of the immunoglobulin and T cell receptor complex V–J and V–D–J JUNCTIONs

VIEW PUBLICATION ⟶

August 4th, 2004|
© 2018 -    |   Invivoscribe, Inc. |   All Rights Reserved